Masitinib | 2007

Cell-permeable. A protein tyrosine kinase (PTK) inhibitor. targeting KIT that is active, orally bioavailable in vivo, and has low toxicity. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases.

Masitinib is a protein tyrosine kinase (PTK) inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases.

2007 | Masitinib DataSheet

Alternate Name/Synonyms: AB-1010

Appearance: Off-white solid

Formulation: N/A

CAS Number: 790299-79-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₈H₃₀N₆OS

Molecular Weight: 498.64

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (>100 mg/ml) or EtOH (4 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent c-KIT, PDGF and FGFR nhibitor

MDL Number: MFCD09954132

PubChem CID: 10074640

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5

InChi: InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3- 11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11, 16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)

InChi Key: WJEOLQLKVOPQFV-UHFFFAOYSA-N